FDA Updates Guidance on Adaptive Clinical Trial Designs for Drugs & Biologics

The updated FDA guidance establishes revised thresholds for Bayesian adaptive trial interim analyses, requiring documented data monitoring committee protocols prior to Phase II initiation. This aims to provide clearer guidelines for the design and execution of clinical trials.